Cardinal Health Q3 Earnings Beats Estimates On Pharmaceutical Segment Strength, Raises Annual Profit Forecast

  • Cardinal Health Inc CAH reported Q3 FY23 adjusted EPS of $1.74, up 20% Y/Y, beating the consensus of $1.49.
  • Sales increased 13% to $50.49 billion, beating the consensus of $49.71 billion.
  • Q3 revenue for the Pharmaceutical segment increased 14% to $46.8 billion, driven by brand and specialty pharmaceutical sales growth from existing customers.
  • Medical segment profit decreased 66% to $20 million, primarily due to lower Product and Distribution volumes and an unfavorable sales mix. 
  • Additionally, these results reflect net unfavorable non-recurring adjustments, including simplification actions and improved PPE margins.
  • Outlook: Cardinal Health raised and narrowed FY23 adjusted EPS guidance to $5.60-$5.80 compared to $5.20-$5.50 expected earlier and the consensus of $5.48.
  • This guidance includes an update to the fiscal year 2023 Pharmaceutical segment profit outlook to 10.5% to 12% growth, from 4% to 6.5% growth, and the Medical segment profit outlook to a decline of approximately 50%, from flat to a decline of 20%. 
  • Price Action: CAH shares are down 1.94% at $80.06 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!